A small primary lung adenocarcinoma found during treatment for a separate gestational cancer

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: TTF-1 positive; napsin A positive.

The 9 mm lung adenocarcinoma was removed with clear margins and described as curatively resected, with CT surveillance continuing every six months.

PubMed CentralRead more →

Immunotherapy and surgery for lung adenocarcinoma with two brain metastases

Patient Info: Anonymized, Female, 50s

Biomarkers: PD-L1 100%; no actionable mutations on next-generation sequencing.

After brain surgery, radiation, 11 cycles of pembrolizumab, and lung surgery, she was off treatment and under observation in remission.

PubMed CentralRead more →

Immunotherapy and surgery for adenosquamous lung cancer with brain metastases

Patient Info: Anonymized, Female, 70+

Biomarkers: PD-L1 positive; no actionable mutations on next-generation sequencing.

After chemotherapy, 19 cycles of pembrolizumab, and right middle lobectomy, she was off immunotherapy and under observation in remission.

PubMed CentralRead more →

Breast cancer with sarcoidosis that mimicked metastatic disease

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2-negative.

Her most recent mammogram showed no recurrent breast cancer while she continued letrozole, goserelin, and six-monthly follow-up.

PubMed CentralRead more →

Non-Small Cell Lung Cancer: Rachel's Survivor Story

Patient Info: Rachel Chua Bradley, Female, 50s

As of April 2021, Rachel had completed treatment for recurrent non-small cell lung cancer, was not on maintenance cancer medication, and returned to MD Anderson every 6 months for checkups.

MD AndersonRead more →

Adenoid cystic cancer of the left breast treated with bilateral mastectomy and tamoxifen

Patient Info: Anonymized, Female, 60s

Biomarkers: BRCA1/2 negative for known pathogenic variants.

The left adenoid cystic carcinoma had not recurred, although a biologically distinct second primary later developed in right axillary ectopic breast tissue.

PubMed CentralRead more →

HER2-positive left breast cancer treated with trastuzumab and mastectomy

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2/CerbB2 strongly positive; BRCA1/2 negative for known pathogenic variants; FANCA variant of uncertain significance.

She remained alive, asymptomatic, and disease-free while undergoing annual surveillance after treatment for the left HER2-positive breast cancer.

PubMed CentralRead more →

Right lobular carcinoma in situ found during follow-up for earlier breast cancer

Patient Info: Anonymized, Female, 60s

Biomarkers: BRCA1/2 negative for known pathogenic variants; FANCA variant of uncertain significance.

She remained alive, asymptomatic, and disease-free while continuing annual laboratory and imaging surveillance.

PubMed CentralRead more →

Lung cancer surgery after a Trousseau syndrome-related stroke

Patient Info: Anonymized, Male, 70+ | Stage III

At 23 months after left pneumonectomy, he had no recurrence and continued outpatient surveillance.

PubMed CentralRead more →

A New Mass Near a BioZorb Implant Was a Foreign-Body Reaction

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2-negative.

Follow-up imaging after a benign biopsy showed no mammographic evidence of malignancy.

PubMed CentralRead more →

A BioZorb-Site Density Two Years After Lumpectomy Was Fat Necrosis

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A new density at the lumpectomy site was confirmed as fat necrosis rather than recurrent cancer during ongoing surveillance.

PubMed CentralRead more →

A New Mass Three Years After Lumpectomy Was Fat Necrosis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A new mass detected three years after treatment was biopsy-proven fat necrosis rather than recurrent cancer.

PubMed CentralRead more →

A Surveillance Asymmetry Near a BioZorb Marker Was Benign Scar and Fat Necrosis

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-positive; PR-positive; HER2-negative.

The new surveillance asymmetry was confirmed as benign fat necrosis, fibrosis, and scar tissue, with follow-up imaging planned.

PubMed CentralRead more →

A Mass Beside a BioZorb Implant Was Fat Necrosis, Not Recurrence

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A 1.8 cm mass detected beside the BioZorb site was confirmed as fat necrosis, with continued imaging follow-up recommended.

PubMed CentralRead more →

Small Masses Near a BioZorb Marker After DCIS Treatment Were Fat Necrosis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive.

Small masses detected three years after DCIS treatment were confirmed as fat necrosis during ongoing surveillance.

PubMed CentralRead more →

A New BioZorb-Site Asymmetry After Triple-Negative Breast Cancer Was Fibrosis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-negative; PR-negative; HER2-negative., triple negative

A new focal asymmetry three years after treatment was confirmed as fibrosis and foreign-body reaction rather than recurrent cancer.

PubMed CentralRead more →

Local Breast Cancer Recurrence Was Found During BioZorb Surveillance

Patient Info: Anonymized, Female, 70+

Biomarkers: Initial right breast tumor: ER-positive, PR-positive, HER2-equivocal. Recurrent right breast tumor: ER-positive, HER2-negative.

Two sites of right-breast recurrence were confirmed three years after lumpectomy, leading to right mastectomy.

PubMed CentralRead more →

Primary pulmonary adenoid cystic carcinoma found with chronic lymphocytic leukaemia

Patient Info: Anonymized, Male, 50s

Biomarkers: Cytokeratin-positive; SMA-positive; p63-positive; TTF-1-negative; S100-negative; CK20-negative; CD56-negative.

Six months after adjuvant radiation, restaging CT showed treatment-related changes without local or metastatic recurrence.

PubMed CentralRead more →

Likely lung carcinoma presenting as bilateral adrenal metastases

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: bilateral adrenal glands

Three months after bilateral adrenalectomy, he remained under regular oncology surveillance, was receiving steroid replacement, and had not required adjuvant chemotherapy.

PubMed CentralRead more →

Silicone lymphadenopathy after treatment for recurrent triple-negative breast cancer

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative; BRCA1-negative; BRCA2-negative; latest recurrence Ki-67 60%–70%.

At the May 2020 follow-up, biopsies confirmed silicone-related lymph-node changes rather than cancer, and imaging showed no recurrent disease while six-monthly surveillance continued.

PubMed CentralRead more →

Right breast cancer with contralateral axillary lymph-node metastasis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Right breast primary: ER-positive; PR-positive; HER2-negative; Ki-67 70%. Left axillary metastasis: ER-positive; PR-negative; HER2-negative; Ki-67 15%; GATA3-positive.

Metastatic Site: contralateral left axillary lymph nodes

Two years after bilateral surgery, clinical and radiological follow-up showed no metastasis or disease recurrence.

PubMed CentralRead more →

Stage IV Colorectal Cancer: Lee's Survivor Story

Patient Info: Lee Jones, Male, 50s | Stage IV

Metastatic Site: Liver

As of February 2021, Lee reported no evidence of colon cancer since 2011 after treatment for Stage IV colon cancer with liver metastases, recurrence, chemotherapy, colon surgery, and liver surgery.

The Patient StoryRead more →

Peutz-Jeghers syndrome / hereditary GI polyposis risk; no confirmed colorectal cancer diagnosis: Kara's Patient Story

Patient Info: Kara, Female

Biomarkers: Peutz-Jeghers syndrome

As of January 2021, Kara had no confirmed invasive cancer but required ongoing Peutz-Jeghers syndrome surveillance; more than 110 polyps had been removed without further bowel resection to reduce obstruction and cancer risk.

Cleveland ClinicRead more →

A regressed choroidal metastasis during EGFR-targeted lung cancer treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion.

Metastatic Site: liver; bone; central nervous system; right choroid

The right choroidal metastasis appeared inactive and regressed during systemic treatment, visual acuity remained 20/20, and no local eye treatment was required.

PubMed CentralRead more →